Drug Trial Radar · NCT03982134
PDR001 + Panobinostat for Melanoma and NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 2019
Primary completion
May 1, 2021
Study completion May 1, 2022
Sponsor
- Lead sponsor
- Muhammad FurqanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Jun 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer (NSCLC)
Conditions
- Melanoma
- Non Small Cell Lung Cancer
Interventions
PDR001Drug
PDR001 is a humanized IgG4 antibody
PanobinostatDrug
Panobinostat is a Histone deacetylase inhibitor (HDACi).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of PDR001 in combination with panobinostat in determining a recommended Phase II doseTime frame: Initiation of treatment up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.